Repurposing an old drug for a new use: Glybenclamide exerts antiplatelet activity by interacting with the thromboxane A2 receptor

Acta Pharmacologica Sinica

Volumn 31, Issue 2, 2010, Pages 150-159

  Ting, Harold J ^a   Murray, Wallace J ^a   Khasawneh, Fadi T ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Antagonist; Drug repurposing; Platelet; Thrombosis; Thromboxane receptor

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CALCIUM; CYCLIC AMP; GLIBENCLAMIDE; SQ29 548; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BLOOD DONOR; CALCIUM MOBILIZATION; CONTROLLED STUDY; HUMAN; IC 50; LIQUID SCINTILLATION COUNTING; RADIOACTIVITY; SPECTROFLUOROMETRY; THROMBOCYTE; THROMBOCYTE AGGREGATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; BINDING SITES; BLOOD PLATELETS; CALCIUM; CYCLIC AMP; GLYBURIDE; HUMANS; HYDRAZINES; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SCINTILLATION COUNTING; SPECTROMETRY, FLUORESCENCE;

EID: 76949098047     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.195     Document Type: Article

References (48)

1. Baglia FA, Shrimpton CN, Emsley J, Kitagawa K, Ruggeri ZM, Lopez JA, et al. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J Biol Chem 2004; 279: 49323-49329
2. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
3. Brisson C, Azorsa DO, Jennings LK, Moog S, Cazenave JP, Lanza F. Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Histochem J 1997; 29: 153-165
4. Du X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Curr Opin Hematol 2007; 14: 262-269
5. Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am 2007; 21: 103-113
6. Reilly M, Fitzgerald GA. Cellular activation by thromboxane A2 and other eicosanoids. Eur Heart J 1993; 14 Suppl K: 88-93.
7. Halushka PV, Mais DE, Mayeux PR, Morinelli TA. Thromboxane, prostaglandin and leukotriene receptors. Annu Rev Pharmacol Toxicol 1989; 29: 213-239
8. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991; 349: 617-620
9. Kim SO, Lim CT, Lam SC, Hall SE, Komiotis D, Venton DL, et al. Purification of the human blood platelet thromboxane A2/prostaglandin H2 receptor protein. Biochem Pharmacol 1992; 43: 313-322
10. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988; 319: 761-767
11. Patrono C, Ciabattoni G, Davi G. Thromboxane biosynthesis in cardiovascular diseases. Stroke 1990; 21 (12 Suppl): IV130-3.
12. Ogletree ML. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc 1987; 46: 133-138
13. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-1141
14. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294
15. Meijer K, Schulman S. Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. Semin Thromb Hemost 2008; 34: 762-771
16. Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol 2009; 44 Suppl 19: 44-52.
17. Pusch G, Feher G, Kotai K, Tibold A, Gasztonyi B, Feher A, et al. Aspirin resistance: focus on clinical endpoints. J Cardiovasc Pharmacol 2008; 52: 475-484
18. Le Breton GC, Venton DL, Enke SE, Halushka PV. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/ endoperoxide receptor. Proc Natl Acad Sci U S A 1979; 76: 4097-4101
19. Nicolaou KC, Magolda RL, Smith JB, Aharony D, Smith EF, Lefer AM. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci USA 1979; 76: 2566-2570
20. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985; 234: 435-441
21. Patscheke H, Stegmeier K, Muller-Beckmann B, Sponer G, Staiger C, Neugebauer G. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death. Biomed Biochim Acta 1984; 43: S312-8.
22. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-185
23. Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005; 4: 78-84.
24. Aronson JK. Old drugs--new uses. Br J Clin Pharmacol 2007; 64: 563-565
25. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007; 448: 645-646
26. McPhie DC. Old drugs, new uses: solving a Hatch-Waxman patent predicament. Food Drug Law J 2004; 59: 155-168
27. Dessi P. [Basic pharmacological research on the hypoglycemic action of N-4-[beta-(2-methoxy-5-chlorbenzamide)-ethyl]-benzosulfonyl-N?-cyclohexylu rea (Glybenclamide)]. Acta Diabetol Lat 1969; 6: 206-221
28. Jin B, Hopfinger AJ. A proposed common spatial pharmacophore and the corresponding active conformations of some TXA2 receptor antagonists. J Chem Inf Comput Sci 1994; 34: 1014-1021
29. Ozaki Y, Yatomi Y, Kume S. Effects of oral hypoglycaemic agents on platelet functions. Biochem Pharmacol 1992; 44: 687-691
30. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B. Thrombininitiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 2007; 117: 953-960
31. Satoh K, Ozaki Y, Yatomi Y, Kume S. Effects of sulfonylurea agents on platelet arachidonic acid metabolism; study on platelet homogenates. Biochem Pharmacol 1994; 48: 1053-1055
32. Pfister SL, Pratt PE, Kurian J, Campbell WB. Glibenclamide inhibits thromboxane-mediated vasoconstriction by thromboxane receptor blockade. Vascul Pharmacol 2004; 40: 285-292
33. Eagle E, Carlson AJ. Toxicity, antipyretic and analgesic studies on compounds including aspirin, phenacetin and 27 derivatives of carbazole and tetrahydrocarbazole. J Pharmacol Exp Ther 1950; 99: 450-457
34. Steiner TJ, Voelker M. Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain. J Clin Pharm Ther 2009; 34: 177-186
35. Michal F, Born GV. Effect of the rapid shape change of platelets on the transmission and scattering of light through plasma. Nat New Biol 1971; 231: 220-222
36. Hung SC, Ghali NI, Venton DL, Le Breton GC. Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes. Biochim Biophys Acta 1983; 728: 171-178
37. Kattelman EJ, Venton DL, Le Breton GC. Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res 1986; 41: 471-481
38. Gilman AG. A protein binding assay for adenosine 3×:5×-cyclic monophosphate. Proc Natl Acad Sci U S A 1970; 67: 305-312
39. Dahlen SE, Kumlin M, Granstrom E, Hedqvist P. Leukotrienes and other eicosanoids as mediators of airway obstruction. Respiration 1986; 50 Suppl 2: 22-29
40. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-1728
41. Ghali NI, Kattelman EJ, Hung SC, Schnorf KE, Le Breton GC, Venton DL. Synthesis of [17,18-3H] trans-13-azaprostanoic acid. A labeled probe for the PGH2/TXA2 receptor. Prostaglandins 1984; 27: 865-876
42. Khasawneh FT, Huang JS, Turek JW, Le Breton GC. Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A2 receptor protein. J Biol Chem 2006; 281: 26951-26965
43. Turek JW, Halmos T, Sullivan NL, Antonakis K, Le Breton GC. Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. J Biol Chem 2002; 277: 16791-16797
44. Drews J. Drug discovery: a historical perspective. Science 2000; 287: 1960-1964
45. Guner OF. History and evolution of the pharmacophore concept in computer-aided drug design. Curr Top Med Chem 2002; 2: 1321-32.
46. Khasawneh FT, Huang JS, Mir F, Srinivasan S, Tiruppathi C, Le Breton GC. Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochem Pharmacol 2008; 75: 2301-2315
47. Rolin S, Dogne JM, Michaux C, Delarge J, Masereel B. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 67-72.
48. Shi MZ, Feng JG, Zheng JJ. A comparison between glibenclamide and glipizide in the treatment of type II diabetes. Zhonghua Nei Ke Za Zhi 1991; 30: 94-7, 126.